| | | | |
CUSIP No. 30205M200 | | 13D | | Page 11 of 14 pages |
Explanatory Note
This Amendment No. 3 to Schedule 13D (“Amendment No. 3”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on August 9, 2019 (as amended to date, the “Schedule 13D”), relating to the shares of common stock, par value $0.0001 per share (the “Common Stock”), of Exicure, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.
Item 5. | Interest in Securities of the Issuer. |
Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:
(a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 8,366,715 shares of Common Stock outstanding as of March 23, 2023, as disclosed in the Issuer’s annual report on Form 10-K filed on March 27, 2023.
| | | | | | | | | | | | | | | | | | | | | | | | |
Reporting Person | | Amount beneficially owned | | | Percent of class | | | Sole power to vote or to direct the vote | | | Shared power to vote or to direct the vote | | | Sole power to dispose or to direct the disposition | | | Shared power to dispose or to direct the disposition | |
The Carlyle Group Inc. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Carlyle Holdings I GP Inc. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Carlyle Holdings I GP Sub L.L.C. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Carlyle Holdings I L.P. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
CG Subsidiary Holdings L.L.C. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
TC Group, L.L.C. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Carlyle Investment Management L.L.C. | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Carlyle Genesis UK LLC | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Abingworth LLP | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Abingworth Bioventures VII LP | | | 287,137 | | | | 3.4 | % | | | 0 | | | | 287,137 | | | | 0 | | | | 287,137 | |
Includes (i) 281,636 shares of Common Stock held of record by Abingworth Bioventures VII LP and (ii) 5,501 shares of Common Stock underlying stock options exercisable within 60 days of the date hereof.